FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Daunorubicin Citrate Liposome Injection (DaunoXome)
Status: Discontinuation
»Therapeutic Categories: Oncology

Galen Limited (New 07/20/2016)

Company Contact Information:
855-425-3646 x6204

Presentation Posting Date Related Information
Daunorubicin Citrate Liposome Injection 2mg/mL (50mg/vial). Sterile, pyrogen-free, preservative-free, single use vial for intravenous infusion. (NDC 10885-001-01). Galen US Inc. N/A Business decision to discontinue product permanently; discontinuation is not due to manufacturing, product quality, safety or efficacy concerns.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English